Navegando por Palavras-chave "clonazepam"

Agora exibindo 1 - 4 de 4
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Clonazepam, um campeão de vendas no Brasil. Por quê?
    (Universidade Federal de São Paulo (UNIFESP), 2016-06-01) Cruz, Nelma Lourenco de Matos [UNIFESP]; Carlini, Elisaldo Luiz de Araujo [UNIFESP]; http://lattes.cnpq.br/5948335656347039; http://lattes.cnpq.br/8459051263596166; Universidade Federal de São Paulo (UNIFESP)
    Clonazepam, a benzodiazepine, is the leading seller in Brazil and the most consumed version of Ordinance 344/98. It is used in the treatment of central nervous system disorders including epilepsy, anxiety, social phobia, insomnia, affective bipolar disorders, panic disorders and akathisia. Clonazepam has high therapeutic efficacy, low toxicity and can lead to dependence after six to eight weeks of use – withdrawal symptoms may occur if there is abrupt discontinuation of use, even in therapeutic doses. This study aims to analyse the various reasons for high sales and consumption of the drug in Brazil. Methodology: the high consumption of clonazepam is a phenomenon of unknown causes and effects; therefore, qualitative research was employed. The focus groups of nineteen patients, five doctors and four pharmacists was formed within two research sites: Funilândia (Minas Gerais) and São Paulo (São Paulo). Interviews were conducted with semi-structured scripts and content analysis with the help of NVivo software. Results – Patients: After use of Clonazepam, patients declared feeling symptoms of sleepiness, relaxation, comfort and security. The range of dosage patients self-administer can be dependent on the emotional state of the users, who do not report taking high doses of clonazepam. The period of use of the drug among patients was up to fifteen years. Information is exchanged between users, and many of them are friends or relatives. Many of them reported being able to get a prescription for clonazepam without receiving medical consultation. Many patients also tried to stop the use of the drug, but were not able to. All of them reported never having received guidance from pharmacists, and only a few received instruction from doctors. Doctors: The main stated reason for prescribing the drug to patients was “renewing a previous prescription from another doctor”. They also declared that were aware of the dosage flexibility, but that the patients do not abusive it. Doctors trust the drug and find it safe, believing that patients use Clonazepam in order to treat ‘problems’. Pharmacists: Pharmacists do not feel co-responsible for the prescription of Clonazepam. They believe that the control of sales of the drug is inefficient and easy to get around – there have been sales of the drug without the correct prescription produced. One of the pharmacists in the study declared that they sell the drug without prescription, something that was witnessed during during the interview. Pharmaceutical laboratories - were not forthcoming in their interest to be a part of the research, and they refused the invitation to participate. Conclusions: The abuse and misuse of Clonazepam is a public health problem. The results of the research indicate failure in the use, the prescription, and the control of sales of Clonazepam. It is necessary to restructure systems that monitor the production, prescription and sales of the drug. Refresher training for health professionals should be encouraged in order to promote rational and sensible use of medicines, especially in the case of psychotropic medicine. Finally, there should be further promotion of actions aimed at users of Clonazepam seeking to educate them about the benefits and risks of using such drugs, self-medication and appropriate use of medicines.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Síndrome das pernas inquietas: diagnóstico e tratamento. Opinião de especialistas brasileiros
    (Assoc Arquivos Neuro- Psiquiatria, 2007-09-01) Aloe, Flávio; Alves, Rosana S Cardoso; Andrade, Luiz Augusto Franco [UNIFESP]; Assis,Márcia; Bacelar, Andrea; Bezerra, Márcio; Cardoso, Francisco [UNIFESP]; Ferraz, Henrique Ballalai [UNIFESP]; Fonseca, Ronaldo Guimarães; Horta, Wagner; Haddad, Mônica Santoro; Hasan, Rosa; Mattos, James Pitágoras; Prado, Gilmar Fernandes do [UNIFESP]; Rizzo, Geraldo; Rodrigues, Nonato; Silva, Ademir Batista da [UNIFESP]; Silva, Delson Jose; Teive, Helio Afonso Ghizoni; Grupo Brasileiro de Estudos em Síndrome das Pernas Inquietas (GBE-SPI); Universidade de São Paulo (USP); Hosp Israelita Albert Einstein; Pratica privada; Practica Privada; Universidade Federal de Minas Gerais (UFMG); Universidade Federal de São Paulo (UNIFESP); UFCE; Universidade Federal de Goiás (UFG)
    This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized by abnormal sensations mostly but not exclusively in the legs which worsen in the evening and are improved by motion of the affected body part. its diagnosis is solely based on clinical findings. Therapeutic agents with efficacy supported by Class I studies are dopamine agonists, levodopa and gabapentine. Class 11 studies support the use of slow release valproic acid, clonazepan and oxycoclone. The GBE-SPI recommendations for management of SPI are sleep hygiene, withdrawal of medications capable of worsening the condition, treatment of comorbidities and pharmacological agents. The first choice agents are dopaminergic drugs, second choice are gabapentine or oxycodone, and the third choice are clonazepan or slow release valproic acid.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Use of benzodiazepines in obsessive-compulsive disorder
    (Lippincott Williams & Wilkins, 2016) Starcevic, Vladan; Berle, David; do Rosario, Maria Conceicao [UNIFESP]; Brakoulias, Vlasios; Ferrao, Ygor A.; Viswasam, Kirupamani; Shavitt, Roseli; Miguel, Euripedes; Fontenelle, Leonardo F.
    This study aimed to determine the frequency of benzodiazepine (BDZ) use in a large sample of patients with obsessive-compulsive disorder (OCD) and ascertain the type of BDZ used and the correlates and predictors of BDZ use in OCD. The sample consisted of 955 patients with OCD from a comprehensive, cross-sectional, multicentre study conducted by the Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders between 2003 and 2009. The rate of BDZ use over time in this OCD sample was 38.4%. Of individuals taking BDZs, 96.7% used them in combination with other medications, usually serotonin reuptake inhibitors. The most commonly used BDZ was clonazepam. Current age, current level of anxiety and number of additional medications for OCD taken over time significantly predicted BDZ use. This is the first study to comprehensively examine BDZ use in OCD patients, demonstrating that it is relatively common, despite recommendations from treatment guidelines. Use of BDZs in combination with several other medications over time and in patients with marked anxiety suggests that OCD patients taking BDZs may be more complex and more difficult to manage. This calls for further research and clarification of the role of BDZs in the treatment of OCD.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Use of benzodiazepines in obsessive-compulsive disorder
    (Lippincott Williams & Wilkins, 2016) Starcevic, Vladan; Berle, David; do Rosario, Maria Conceicao [UNIFESP]; Brakoulias, Vlasios; Ferrao, Ygor A.; Viswasam, Kirupamani; Shavitt, Roseli; Miguel, Euripedes; Fontenelle, Leonardo F.
    This study aimed to determine the frequency of benzodiazepine (BDZ) use in a large sample of patients with obsessive-compulsive disorder (OCD) and ascertain the type of BDZ used and the correlates and predictors of BDZ use in OCD. The sample consisted of 955 patients with OCD from a comprehensive, cross-sectional, multicentre study conducted by the Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders between 2003 and 2009. The rate of BDZ use over time in this OCD sample was 38.4%. Of individuals taking BDZs, 96.7% used them in combination with other medications, usually serotonin reuptake inhibitors. The most commonly used BDZ was clonazepam. Current age, current level of anxiety and number of additional medications for OCD taken over time significantly predicted BDZ use. This is the first study to comprehensively examine BDZ use in OCD patients, demonstrating that it is relatively common, despite recommendations from treatment guidelines. Use of BDZs in combination with several other medications over time and in patients with marked anxiety suggests that OCD patients taking BDZs may be more complex and more difficult to manage. This calls for further research and clarification of the role of BDZs in the treatment of OCD.